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A B S T R A C T
The intention behind the present work was to develop a microsponge based novel dosage
form for sustained delivery of domperidone. Quasi-emulsion solvent diffusion method was
employed using Eudragit RS-100 with various drug–polymer ratios for the preparation of
microsponges. For optimization purposes, several factors which affect microparticles’ physi-
cal properties were investigated. Characterization techniques followed for the formed
microsponges were DSC, FTIR, SEM, XRD and particle size analysis, along with morphol-
ogy, drug loading and in vitro drug release. It was found that there were no chemical
interactions between drugs and polymers used as per DSC and FTIR results. The drug–
polymer ratio showed remarkable impact on drug content, encapsulation efficiency and particle
size. SEM micrographs revealed that microsponges were spherical in shape with porous surface,
and had 104 ± 0.22 µm mean particle size. The microsponges were then loaded in capsules
followed by in vitro drug release study; which depicted that microsponges with drug–
polymer ratio of 1:2 were more proficient to give extended drug release of 76.38% at the
end of 8 h, superior in contrast to conventional marketed formulation Domstal®, which got
exhausted incredibly earlier by releasing 82.57% drug at the end of 1⁄2 h only. Hence, the
developed microsponge based formulation of domperidone would be an expectant, prom-
ising substitute to conventional therapy of gastroparesis, emesis and alike gastric ailments.
© 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Shenyang Phar-
maceutical University. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
The oral route of drug administration is known to be the most
convenient and commonly employed route. Drugs that get easily
absorbed in the gastrointestinal tract and having a short half-
life get eliminated rapidly through blood circulation. To shun
these problems, orally controlled release formulations have been
developed, which release drug slowly into the gastrointesti-
nal tract and help in keeping constant drug concentration in
the serum for a longer period of time. Oral route of drug ad-
ministration has broad acceptance. Up to 50–60% of oral solid
dosage forms are well-liked because of usual, straightfor-
ward and suitable administration with precise dosage, self-
medication, pain evasion and most prominently patient
compliance. The most admired solid dosage forms are tablets
and capsules; these dosage forms may envelop wide range
of applications in novel drug delivery systems such as
nanoparticles, microparticles, microspheres, nanospheres and
microsponges [1]. Microsponge Delivery System (MDS) is highly
cross-linked, porous, polymeric microspheres that can entrap
broad range of active ingredients and release them into the
skin over an extended period of time and in response to triggers.
This system was implied earlier for the enhancement of per-
formance of drugs. It is a unique technology for the controlled
release of drug, which consists of microporous beads loaded
with active agents [2,3].
One of the major challenges faced by pharmaceutical sci-
entists is to control the delivery rate of actives to a
predetermined site in the body. The prime aim of any drug de-
livery system is to provide therapeutic amount of drug to a
proper site in the body, to punctually achieve and maintain the
desired drug concentration. Most of these drug delivery systems
include polymers which encapsulate drug. Oral drug delivery
systems are used for enhancing therapeutic index of the drug
and also for reducing side effects. Oral route is the chosen route
for the administration of active and/or therapeutic agents owing
to its low cost of therapy and ease of administration, which
may lead to higher level of patient acquiescence. The effi-
cient oral drug delivery may depend upon several factors like
gastric emptying, gastrointestinal transit time of the drug or
dosage form, drug release from designed dosage form and site
of absorption of drug [4–7].
The microsponge technology was developed by Won in 1987,
and the original patents were assigned to Advanced Polymer
Systems, Inc. Microsponges are porous microspheres having
myriad of interconnected voids of particle size ranging between
5 and 300 µm.They are used as a carrier system since they have
the capacity to entrap a wide range of actives in their non-
collapsible structures with porous surface, through which active
ingredients are released in a controlled manner [8]. Further
these microsponges with actives can be incorporated into for-
mulations such as tablets, capsules, creams, gel, lotions and
powders and share a broad package of benefits [9–14]. The fun-
damental appeal of the microsponge technology stems from
the intricacy experienced with conventional formulations in
releasing active ingredients over an extended period of time.
Conventional formulations typically provide actives in rela-
tively high concentrations but with a short duration of action;
leading to a cycle of short-term overmedication followed by
long-term undermedication. In contrast, microsponges offer
an advantage of programmable drug release and are biologi-
cally harmless.This technology also offers entrapment of active
pharmaceutical ingredients contributing toward improved sta-
bility, increased elegance, enhanced formulation flexibility and
reduced side effects [8].
Domperidone (DOM) is a synthetic benzimidazole
compound, chemically known as 5-chloro-1-(1-[3-(2-oxo-2,3-
dihydro-1H-benzo[d]imidazol-1-yl)propyl]piperidin-4-yl)-1H-
benzo[d]imidazol-2(3H)-one [15,16]. It is known to have gastro
prokinetic and anti-emetic activity and normally imple-
mented for managing upper gastrointestinal tract motility as
well as gastroparesis by blocking the Dopamine (D2) recep-
tors at the chemoreceptor trigger zone (CTZ) in the area
postrema and also at the gastric region [17]. It is rapidly ab-
sorbed from the stomach and the upper part of the GIT by active
transport, after oral administration, and few side effects have
been reported. It is a weak base with good solubility in acidic
pH, but in alkaline pH, the solubility is significantly reduced
[16]. It is poorly water soluble (log P, 3.1) and has low absorb-
ability after oral administration, and undergoes extensive first
pass metabolism; leading to poor bioavailability of 15% [18].
Its onset of action is about 30 min when administered as con-
ventional tablet or capsule dosage form and the effect lasts
for nearly 4–7 h. It is not detectable in blood after a few hours
of oral administration in healthy subjects as it gets elimi-
nated in 5–7 h from the body [19]. Moreover, as it is supplied
at low dose (10 mg) and has low molecular weight
(425.9 gm/mol), it entails long term treatment and repetitive
dosing, making DOM an appealing contender for develop-
ment of a sustained release formulation [18].
Thus, the aim of our study was to prepare sustained release
DOM microsponge based capsules using polymer like Eudragit
RS 100, with reduced frequency and side effects, for effective
gastroparesis, emesis and other such ailments therapy. A com-
parative study of all the formulations prepared by quasi-
emulsion solvent diffusion method was aimed and the effects
of drug–polymer ratios and external phase compositions used
on release kinetics have also been studied.
2. Materials and methods
2.1. Materials
DOM was procured from Vasudha Pharma, Hyderabad, India.
Eudragit RS 100 as a gift sample was provided by Evonik Pharma,
Mumbai, India. Dichloromethane and dibutyl phthalate were
purchased from Qualigens Fine Chemicals, Mumbai, India. Poly-
vinyl alcohol (PVA) was procured from CDH Pvt. Ltd. Mumbai,
India. All the other ingredients used were of analytical grade,
and were used as procured.
2.2. Methods
2.2.1. Characterization of pure drug
2.2.1.1. Melting point. Melting point of DOM was determined
by micro controlled based melting point apparatus (SMP10/1,
443a s i an j o u rna l o f p h a rma c eu t i c a l s c i e n c e s 1 0 ( 2 0 1 5 ) 4 4 2 – 4 5 1
Stuart, UK). The sample was inserted in capillary tube having
one end closed. Then the capillary tube was inserted in bath
of silicone oil, which was heated in a controlled manner with
the help of electrical heating coil. The temperature at which
the drug sample started melting was noted as the melting point
temperature. Average of triplicate readings was noted and com-
pared with the literature value.
2.2.1.2. Differential scanning calorimetry (DSC). About 5 mg of
the sample was sealed in the aluminum pans and heated at
the rate of 10 °C/min, covering a temperature range of 40 °C
to 300 °C under nitrogen atmosphere at flow rate of
100 ml/min, and DSC thermogram (Mettler-Toledo DSC 821e,
Switzerland) for pure drug was obtained. Indium standard was
implied for calibrating DSC enthalpy and temperature scale.
2.2.1.3. FTIR spectroscopy. FTIR spectra were recorded (FTIR,
A-410, Jasco, Japan) over wavelength range of 4000 to 500 cm−1
at resolution of 4 cm−1 [2,3,20–23]. Samples were dispersed in
KBr and compressed in pellets by applying 5 tons pressure for
5 min using hydraulic press. Formed pellets were kept in light
path and spectra were recorded.
2.2.1.4. UV spectroscopy. Calibration curve of DOM was plotted
using 0.1 N HCl. The drug was analyzed spectrophotometri-
cally (Pharmaspec 1700, Shimadzu, Japan) and curve was found
to be linear in the range of 2–20 µg/ml and regression coeffi-
cient (r2) was found to be 0.998 at 283.5 nm.
2.2.2. Drug–excipient interaction study
Drug–excipient interactions were investigated by FTIR and DSC
studies. IR spectra were recorded to check compatibility of drug
with excipients, using FTIR spectrophotometer (FTIR, A-410,
Jasco, Japan). DSC helps in assessing physical properties of the
sample nature (crystalline or amorphous) and indicates any
probable interaction among drug and excipients. DOM and
physical mixture (DOM and Eudragit RS 100) were subjected
to thermal analysis.
2.2.3. Preparation of DOM microsponges
The microsponges containing DOM were prepared by quasi-
emulsion solvent diffusion method [2,3,24] using an internal
phase that consisted of Eudragit RS-100 and dibutyl phthal-
ate (1% w/v) dissolved in 5 ml of dichloromethane:ethanol (1:1).
Dibutyl phthalate was added to enhance the plasticity of the
polymer. This was followed by the addition of DOM dissolved
under ultrasonication at 35 °C. The mixture was then poured
into aqueous solution of PVA which served as the external phase
with 60 min stirring at 400 rpm.The microsponges were formed
due to the removal of dichloromethane and ethanol from the
system by evaporation. Prepared microsponges were then fil-
tered, washed with distilled water and subjected to drying at
40 °C for 12 h in hot air oven. Lastly microsponges obtained
were weighed to determine production yield. Various formu-
lation batches were prepared as per Table 1.
2.2.4. Evaluation of DOM microsponges
2.2.4.1. Differential scanning calorimetry (DSC). Thermogram
of DOM microsponge formulation was obtained using differ-
ential scanning calorimeter (Mettler-Toledo) DSC 821e outfitted
with an intercooler.
2.2.4.2. Infrared spectroscopy. It was done using Fourier Trans-
form Infrared Spectrophotometer (FTIR A-410, Jasco, Japan) using
KBr pellet method. FTIR spectra of DOM, Eudragit RS 100, physi-
cal mixtures of DOM and Eudragit RS 100, and microsponge
formulation were recorded in the wavelength range of 4000 to
500 cm−1.
2.2.4.3. Production yield. Microsponges production yield was
determined by the formula mentioned below [2,25]:
Production yield PY
Practical mass of microsponges
Theoret
( ) =
ical mass polymer drug+( )
× 100 (1)
2.2.4.4. Actual drug content and encapsulation efficiency. The
weighed amount of drug loaded microsponges (100 mg) was
kept in 100 ml 0.1 N HCl solution for 12 h with continuous stir-
ring. Filtered samples (using 0.45 µm membrane filter) were
analyzed at 283.5 nm against blank using UV spectrophotom-
eter (Pharmaspec 1700, Shimadzu, Japan). Estimation of drug
content and encapsulation efficiency for all batches were done
using the following expressions [3,20]:
Actual drug content
M
M
act
ms
%( ) = × 100 (2)
Encapsulation efficiency
M
M
act
the
= × 100 (3)
where Mact = actual DOM content in weighed quantity of
microsponges, Mms = weighed quantity of microsponges and
Mthe = theoretical DOM content in microsponges.
2.2.4.5. Scanning electron microscopy (SEM). For assessing mor-
phology and surface topography, prepared microsponges were
Table 1 – Composition of DOM microsponges.
Ingredients Formulation batches
M1 M2 M3 M4 M5 M6 M7 M8 M9
Domperidone:Eudragit RS 100 (mg) 1:1 1:2 1:3 1:4 1:5 1:3 1:3 1:3 1:3
Dichloromethane:Ethanol (1:1, ml) 5 5 5 5 5 5 5 5 5
Dibutyl phthalate (% w/v) 1 1 1 1 1 1 1 1 1
Polyvinyl alcohol (mg) 50 50 50 50 50 30 40 60 70
Water (ml) 100 100 100 100 100 100 100 100 100
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examined under scanning electron microscope (LEO 440i, UK)
operating at 5 kV. By means of double adhesive tape, samples
were mounted on a metal stub and coating with platinum/
palladium alloy under vacuum was done [5].
2.2.4.6. Particle size analysis. Particle size analysis of pre-
pared microsponges was carried by using Malvern Mastersizer
(Hydro 2000 SM, Malvern Instruments, UK). Microsponges were
dispersed in double distilled water before running sample in
the instrument to ensure that the light scattering signal, as in-
dicated by particles count per second, was within instrument’s
sensitivity range. Analysis was carried out at room tempera-
ture, keeping the angle of detection at 90°. The average particle
size was expressed in terms of d(0.9) µm [9].
2.2.4.7. X-ray diffraction study. X-ray powder diffraction (XRPD)
patterns were recorded by using X-ray diffractometer (Siemens,
Model D5000, Germany) with CuKα radiation of wavelength
1.5405 A° and a crystal monochromater. The instrument was
operated at voltage 45 mV and current 20 A. Diffraction pat-
terns were run at 5 to 10 °C/min in terms of 2θ; crystal and
physical states of DOM were characterized.
2.2.5. Preparation of DOM microsponge capsules
For preparing microsponge based capsules, DOM microsponges
containing drug equivalent to marketed formulation contain-
ing unentrapped drug (DOMSTAL®) were accurately weighed
and filled into hard gelatin capsules.
2.2.6. Evaluation of DOM microsponge capsules
2.2.6.1. In vitro drug release. The in vitro drug release from dif-
ferent batches of microsponge filled capsules was evaluated
(in triplicate) in 900 ml of 0.1 N HCl (pH 1.2) using USP type II
dissolution apparatus (TDT-08L, Electrolab, Mumbai, India) for
8 h under sink conditions with 50 rpm paddle rotation speed
at 37 ± 0.5 °C. Aliquots of 5 ml were withdrawn at different
time intervals and replaced with the same volume of fresh
dissolution medium. Filtered samples were assayed spectro-
photometrically at 283.5 nm.
2.2.6.2. Stability study. Optimized capsule formulation was sub-
jected to stability testing as per ICH norms. Capsules were blister
packed and various replicates were kept at 40 ± 2 °C and 75 ± 5%
RH in a humidity chamber. Capsules were assessed for change
in appearance and in vitro release profile at an interval of 30,
60 and 90 ds.
3. Results and discussion
3.1. Characterization of pure drug
3.1.1. Melting point
Melting point of DOM was found to be in the range of
241–243.9 °C (literature standard 242.5 °C). As experimental
values were in good agreement with standard, procured drug
was supposed to be pure.
3.1.2. Differential scanning calorimetry (DSC)
As reflected by DSC thermogram (Fig. 1A), a sharp endother-
mic peak was observed at 243.83 °C corresponding to the
melting point of drug in the crystalline form, reflecting drug
purity.
3.1.3. FTIR spectroscopy
FTIR spectrum of procured DOM was recorded (Fig. 2A) and
spectral interpretation was done. The characteristic IR
Fig. 1 – DSC thermogram of (A) DOM, (B) physical mixture and (C) microsponge formulation.
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absorption peaks of DOM at 3020.41 cm−1 (N—H stretching),
2817.80 cm−1 (C—H stretching), 1689.67 cm−1 (C=O stretch-
ing), 1622.47 cm−1 (C=C stretching), 1384.77 cm−1 (C—H bending)
and 834.22 cm−1 (C—Cl bending) were reflected in the drug
sample spectrum, which confirmed the purity of DOM.
3.2. Drug–excipient interaction study
Compatibility study was carried out using DSC and FTIR studies,
to check for any possible interaction between the drug and the
excipients used. In DSC studies, physical mixture showed similar
thermal behavior to that of pure drug but with lower inten-
sity (Fig. 1B). Pure DOM thermogram reflects an endothermic
peak at 243.83 °C corresponding to its melting point (Fig. 1A).
However, the melting endotherm of microsponge formula-
tion was suppressed, corresponding to partial protection of DOM
since microsponge encapsulation (Fig. 1C). It was also ob-
served that DOM crystallinity altered significantly in
microsponge formulation, confirming its dispersion in the
system.
FTIR spectroscopic study results discovered no any new peak
appearance or disappearance of existing peaks, discarding any
chemical interaction probability among drug and polymer used.
The characteristic ketone C=O stretching vibration at
1687.69 cm−1, C—H stretching at 2816.10 cm−1, C—H bending at
1375.77 cm−1, C—Cl stretch at 839.42 cm−1 and N—H stretch-
ing from 3019.28 to 3068.78 cm−1 were recognized in all spectra
(Fig. 2). All characteristic peaks of DOM were experiential in
physical mixture and microsponge formulation spectrum
(Fig. 2B and 2C).Thus, IR spectroscopy results depicted that DOM
was compatible with selected polymer, excipients and possess
good stability in all microsponge formulations.
3.3. Evaluation of DOM microsponges
3.3.1. Physical appearance
White to almost white, microsponge particles were obtained
by quasi-emulsion solvent diffusion method. Flow properties
of pure drug were noted to be poor, while it has been ob-
served that microsponges of DOM were having good flow
properties.
3.3.2. Production yield
The production yield of all batches was observed in the range
of 31.78% to 79.45% (Table 2). It was found that production yield
Fig. 2 – Overlain FTIR spectra of (A) DOM, (B) physical mixture and (C) optimized microsponge formulation.
Table 2 – Actual drug content, encapsulation efficiency, production yield and % CDR (n = 3).
Batches Drug:
polymer
ratio
PVA
concentration
(mg)
Theoretical
drug
content (%)
Actual
drug
content (%)
Encapsulation
efficiency (%)
Production
yield (%)
% CDR Flux
(mg/cm2 h)
M1 1:1 50 50 46.07 ± 0.21 92.20 ± 0.43 31.78 ± 0.58 85.74 ± 0.11 0.3239
M2 1:2 50 33.33 29.00 ± 0.23 87.01 ± 0.70 48.54 ± 0.38 76.38 ± 0.10 0.2886
M3 1:3 50 25 21.22 ± 0.17 84.90 ± 0.68 55.52 ± 0.31 67.19 ± 0.09 0.2538
M4 1:4 50 20 16.25 ± 0.08 81.25 ± 0.44 73.02 ± 0.73 55.45 ± 0.16 0.2094
M5 1:5 50 16.66 12.15 ± 0.17 72.52 ± 0.49 79.45 ± 0.62 44.13 ± 0.10 0.1667
M6 1:3 30 25 19.05 ± 0.05 76.20 ± 0.2 35.90 ± 0.48 70.51 ± 0.05 0.2663
M7 1:3 40 25 19.98 ± 0.05 79.96 ± 0.02 48.98 ± 0.06 68.39 ± 0.14 0.2583
M8 1:3 60 25 22.24 ± 0.01 88.98 ± 0.04 60.48 ± 0.39 65.38 ± 0.06 0.2469
M9 1:3 70 25 22.57 ± 0.05 90.29 ± 0.02 68.22 ± 0.22 63.49 ± 0.22 0.2398
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was greatly affected by drug:polymer ratio as well as by con-
centration of polyvinyl alcohol. Moreover, increase in the
drug:polymer ratio resulted into increased production yield.
When drug:polymer ratio was 1:1 (M1), the production yield
was very low, i.e. 31.78%, while for drug:polymer ratio 1:5 (M5)
it was 79.45%. With the low concentration of polyvinyl alcohol
(30 mg, M6), the production yield was quite low, i.e. 35.9%. As
the concentration of polyvinyl alcohol was increased (from
30 to 70 mg), the production yield was also found to be
increased. This was for the reason that the abridged
dichloromethane diffusion rate from concentrated solutions
to aqueous phase at higher drug:polymer concentrations pro-
vides additional time for formation of droplet, thereby improving
yield.
3.3.3. Actual drug content and encapsulation efficiency
At all ratios of drug:polymer employed, the mean amount of
drug entrapped in the prepared microsponges was lower than
the theoretical value, since the drug loading efficiency did not
reach 100%.This could be attributed to dissolution of some drug
in the solvent or aqueous phase employed. The results of en-
capsulation efficiency showed that higher drug loading
efficiencies were attained at lower drug:polymer ratios. Use of
the higher amounts of polyvinyl alcohol, while preparing
microsponges at higher polymer:drug ratios caused slightly in-
creased viscosity of the dispersed phase. When solvents were
diffused out, nearly all of the dispersed phase was converted
to solid microsponges and estranged particles emerged. The
reason behind utmost drug loading efficiencies for these for-
mulations was availability of maximum polymer amount to
each drug unit in contrast to the rest of formulations. The en-
trapment efficiency was noted in the range of 72.52–92.20% as
shown in Table 2.
3.3.4. Scanning electron microscopy (SEM)
Morphology and surface topography of prepared microsponges
were discovered by SEM analysis. The representative SEM
images of microsponges are shown in Fig. 3A and 3B. SEM
results indicated that microsponges formed were highly porous,
predominantly spherical and not much entire DOM crystals
were observed visually. By diffusion of solvent from surface of
microsponges, pores were induced. Moreover, it was exposed
that the distinctive internal structure comprised spherical cavity
enclosing a stiff shell assembly of drug and polymer. The
Fig. 3 – (A, B) SEM and (C, D) PPL microscopic images of microsponges.
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internal structure consisted of numerous annulled spaces and
appearance of particles was such that they were perfect to be
called microsponges.
The microsponges were also observed under binocular plane
polarized light (PPL) microscope (Fig. 3C and 3D), which showed
that formed microsponges were spherical in each single entity
or in form of bunches and had porous nature.
3.3.5. Particle size analysis
The mean particle size of microsponge formulations should
be in the range of 5–300 µm. Visual inspection of all batches
for particle size using optical microscope revealed that the par-
ticle size was increased with increase in Eudragit RS 100
amount, i.e. with an increase of drug:polymer ratio. This might
be due to the fact that polymer available at higher drug:polymer
ratio was in greater amount thereby increasing polymer wall
thickness, which consequently led to larger microsponges. In
addition, with increasing amount of polyvinyl alcohol, par-
ticle size was found to be increased, credited to the rise in
apparent viscosity at increased stabilizer concentrations. It
results in larger emulsion droplet formation and finally in
greater microsponge size [4,5,9,25–28]. Optimized batch pos-
sessed greater percentage of intact, uniform, spherical particles
during optical microscopy, hence subjected to analysis using
photon correlation spectroscopy (Malvern Mastersizer Hydro
2000 SM, Malvern, UK). The results indicated particle size d(0.9)
corresponding to 104 ± 0.22 µm.
3.3.6. X-ray diffraction study
To evaluate physicochemical characteristics of prepared
microsponges, XRPD method was implied. In X-ray
diffractogram, sharp peaks at diffraction angle (2θ) 14° were
obtained in both DOM and its microsponge formulation (Fig. 4A
and 4B).
For determination of occurrence of crystal habit modifica-
tions and polymorphs in drug crystals, XRPD is a valuable
technique. In general when diffraction patterns are identical
for two forms of crystals, they are known to possess the
same internal structures and when patterns are nonidenti-
cal, crystals have diverse internal structures known as
polymorphs. In the present study, samples depicted spectra
with similar peak positions (2θ values). Consequently,
no existence of polymorphs of DOM in these samples was
verified.
Additionally, for crystallinity determination, a compari-
son of some representative peak heights with those of a
reference in diffraction patterns has been done. Final formu-
lation of microsponges showed peaks at diffraction angle similar
to that of XRD pattern of DOM but with some lower intensity,
indicating its crystalline nature. The relative degree of crys-
tallinity (RDC) value was found to be 1.47. So XRPD analysis
revealed that the crystalline nature of drug was not com-
pletely lost and was found to remain thermally stable in the
final formulation as well.
3.4. Evaluation of DOM microsponge capsules
3.4.1. In vitro drug release
The drug release was observed to decline within range of 85.74%
to 44.13% with respect to rise in drug:polymer ratio from 1:1
to 1:5. The reason behind this is as drug:polymer ratio has in-
creased, in each microsponge, to encapsulate drug, the polymer
amount available was greater. It led to thickening of the polymer
matrix wall, thus extending diffusion path and ultimately less-
ening drug release. The highest drug release, i.e. 85.74% was
found for the formulation M1, while the lowest, 44.13%, was
found for M5. Initial burst release observed in formulations of
M1 and M2 can be allocated to the existence of non-
encapsulated drug near the surface or on the exterior of
microsponges. Graphical presentation for comparative drug
release of all batches M1–M5 and M6–M9 are shown in Fig. 5A
and 5B respectively.
Fig. 4 – XRD patterns of (A) DOM and (B) microsponge formulation.
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It has been reported that for each formulation from M6 to
M9, the drug release went on decreasing with increasing
amount of PVA. This could be attributed to the fact that a
polymer matrix releases drug after complete swelling of polymer
and the time required for swelling of polymer is directly pro-
portional to stabilizer concentration. The slight decrease in
release rate with increased PVA amount was from 70.51% to
44.13% for formulations M6–M9.
3.4.2. Release profile of marketed formulation
The drug release study for conventional marketed formula-
tion containing pure, unentrapped DOM was carried out; release
profile obtained for was as depicted in Fig. 5C. The conven-
tional formulation released 82.57% drug at the end of 1⁄2 h only
and got exhausted. In contrary microsponge based formula-
tion, drug is released gradually up to 8 h, and thereby would
be effective in minimizing gastric irritation, eczema, ulcers and
other side effects. As M2 batch formulation exhibited drug
release 76.38% after completion of 8 h, and was also found su-
perior in terms of physiochemical characterization, production
yield, actual drug content, entrapment efficiency, morphol-
ogy, surface topography, particle size, percentage of intact porous
microsponges and other physical parameters, in addition to
drug release, it is assumed to be the best and most efficient
formulation to give an extended drug release among the all
formulations [2,3,9].
3.4.3. In vitro drug release kinetic study
The in vitro release data were subjected to various release
models, namely, zero order, first order, Higuchi, Peppas, Hixson–
Crowell and Korsmeyer–Peppas, and best fit model was decided
by highest r2 value. The in vitro drug release showed highest
regression value for the Peppas model (0.997 for M5). On the
basis of maximum regression value, Peppas model was found
to be best fit for most of the formulations (Table 3). The drug
release mechanism for all microsponge formulations was
studied by putting release data in Korsmeyer equation. For for-
mulations M1–M9, n values were found in the range 0.5614–
0.7278, while the n value for Korsmeyer–Peppas model was seen
to be in the range 0.5–1, which indicates non-Fickian diffusion.
3.4.4. Effect of formulation variables on DOM microsponges
3.4.4.1. Effect of drug–polymer ratio. Increase in drug:polymer
ratio (M1–M5) has been found to result from increase in
Fig. 5 – Comparative drug release profiles of (A) M1–M5, (B) M6–M9 and (C) marketed formulation (n = 3, mean ± SD).
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production yield, while drug content, encapsulation effi-
ciency and percent drug release were found to be decreased
(Table 2). The reason behind this is as drug:polymer ratio went
on increasing, the polymer amount available for each
microsponge to encapsulate the drug was greater, thus result-
ing to rising polymer matrix wall thickness which led to
extended diffusion path and ultimately to lesser drug release.
Consequently the amount of drug diffused and flux of the for-
mulations were decreased at higher drug:polymer ratio.
3.4.4.2. Effect of composition of external phase. Composition of
external phase was altered for formulations M6–M9 by chang-
ing the concentration of PVA from 30 to 70 mg. It has been
observed that in increasing the amount of PVA, production yield,
encapsulation efficiency and particle size were increased while
slight decrease in drug release was noticed (Table 2).
3.4.5. Stability study
During stability studies formulation appearance was found to
be similar to the time of blister packaging, with no signifi-
cant brittleness and plasticity of shells. It was also noted from
outcomes that there were no considerable changes in drug
content as well as percentage of drug release. Therefore no evi-
dence of degradation of drug was observed.
After comparison of drug release profiles of optimized for-
mulation M2 before and after 3 months stability study, similarity
factor (f2) was calculated (Fig. 6). It was found to be f2 = 86.60
(>50); similarity factor greater than 50 indicates good stabil-
ity of the product. In view of this it was concluded that the
formulation was stable over the period of 3 months.
4. Conclusions
The present study reported development of DOM loaded
microsponges using Eudragit RS 100 by quasi-emulsion solvent
diffusion method. The aim behind developing an oral poly-
meric microsponge delivery system was to deliver DOM in a
sustained manner for an extended period of time, to reduce
frequency of administration and to improve its bioavailability.
The primary benefit of such formulations is more uniform
maintenance of blood plasma level of therapeutic agent, which
is useful to shun unwanted peak and trough patterns achieved
with multiple immediate release formulations. Therefore, in
the present study, sustained release formulation of DOM was
prepared by incorporating it in polymeric microsponges. Pre-
pared microsponges were then incorporated in capsule dosage
form. The quasi-emulsion solvent diffusion method imple-
mented was found to be simple, reproducible and rapid. Formed
microsponges were spherical in shape, have high porosity and
good flow.Varied drug–polymer ratio reflected remarkable effect
on particle size, drug content and encapsulation efficiency. The
in vitro drug release showed highest regression value for the
Peppas model. Formulation with 1:2 drug:polymer ratio was
found to be more efficient to give extended drug release (76.38%
at 8 h). With respect to conventional formulation, these
microsponges are expected to remain in the stomach for a
longer time as buoyant, gradually releasing their contents over
the time. Optimized formulation subjected to stability study
showed no significant change in diverse parameters and hence
indicated a stable formulation. Thus, DOM microsponges pre-
pared in this study were found to be promising as newfangled
delivery system offering prolonged release of DOM and hence
would be more useful than conventional formulation therapy.
Table 3 – Release kinetics data of microsponge formulations.
Batch code Zero order First order Higuchi Peppas Korsmeyer–Peppas
parameters
Best fit model
n* k*
M1 0.9567 0.9761 0.9873 0.9896 0.5614 2.468 Peppas
M2 0.9679 0.9818 0.9782 0.9823 0.5810 1.9873 Peppas
M3 0.9734 0.9860 0.9747 0.9861 0.5901 1.5951 Peppas
M4 0.9832 0.9934 0.9722 0.9950 0.6614 0.8894 Peppas
M5 0.9881 0.9961 0.9679 0.9970 0.7278 0.4876 Peppas
M6 0.9711 0.9850 0.9766 0.9866 0.5881 1.7494 Peppas
M7 0.9862 0.9850 0.9748 0.9856 0.5892 1.6435 Zero order
M8 0.9727 0.9857 0.9726 0.9865 0.5892 1.5557 Peppas
M9 0.9727 0.9843 0.9736 0.9865 0.5814 1.5814 Peppas
* n – kinetic constant, k – release rate constant.
Fig. 6 – Drug release profile of microsponge based
formulation during stability study.
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